Transformational Power of Genomics in Pharma
Summary
Accelerating technologies within the genomics landscape:
Several advancements in the pharmaceutical industry have enabled the field of genomics to expand, with researchers innovating new means of therapy for patients with a wide variety of diseases, subsequently enabling in-depth insights to be generated within the genomics landscape. Genomics therapies are paving the way for novel treatments that address the root cause of diseases, allowing additional resources to be allocated for efficient precision and personalized medicine therapies for the treatment of rare diseases with niche and low patient populations.Scope
- A dedicated report examining the pivotal healthcare, technological, macroeconomic, and regulatory trends shaping the genomics field in pharma landscape. This report also provides an in-depth analysis of how these trends are poised to either accelerate progress or create obstacles for the growth of the genomics market.
Reasons to Buy
- Understand the key trends accelerateing or hindering the genomics field in pharma space. See market forecasts for different therapies up to 2028. Understand recent and influential developments in genomics. Review of leaders and challengers across the genomics value chain.
Table of Contents
- Executive summary
- Players
- Thematic Briefing
- Trends
- Healthcare trends
- Technology trends
- Macroeconomic trends
- Regulatory trends
- Industry Analysis
- Market size and growth forecasts
- Survey data
- The analyst's genomics potential and impact on the pharma industry surveys, 2024-25
- Pharma case studies
- LPKF Laser & Electronics’ CellShepherd can significantly improve single-cell analysis
- QIAGEN’s two advanced tools aim to enhance microbial analysis
- Profluent develops OpenCRISPR-1, a GenAI-based gene editor
- Eligo Bioscience develops an undisruptive bacterial genome editing technology within the gut
- Signals
- M&A trends
- Strategic partnerships
- Funding deals
- Social media trends
- Value Chain
- Next-generation sequencing
- Bioinformatics
- Gene therapy
- Companies
- Public companies
- Private companies
- Sector Scorecards
- Drug development sector scorecard
- Who’s who
- Thematic screen
- Valuation screen
- Risk screen
- Bibliography
- Appendix
- Abbreviations
- Further Reading
- The analyst reports
- Thematic Research Methodology
- About the Analyst
- Contact the Publisher
Table 1: Healthcare trends in the genomics space
Table 2: Technology trends in the genomics space
Table 3: Macroeconomic trends in the genomics space
Table 4: Regulatory trends in the genomics space
Table 5: Examples of M&As in the genomics space, 2023-25
Table 6: Examples of strategic partnerships in the genomics space, 2023-25
Table 7: Examples of funding deals in the genomics space, 2023-25
Table 8: Comparison of the different types of next-generation sequencing
Table 9: Public companies
Table 10: Private companies
Table 11: the analyst reports
List of Figures
Figure 1: Who are the leading players in the genomics space?
Figure 2: Global forecast sales of genomics-based medicine by key molecule type, 2024-2030
Figure 3: Which of the following areas do you believe genomics has the most potential to impact the pharmaceutical industry?
Figure 4: Which emerging genomic technology do you believe will have the greatest impact on pharmaceutical advancements over the next decade?
Figure 5: What do you see as the biggest challenge in integrating genomics into pharmaceutical practices?
Figure 6: Top influencer trends related to genomics
Figure 7: Top influencer posts related to genomics, 2025
Figure 8: The genomics value chain
Figure 9: Top companies for genomics drugs
Figure 10: Examples of leaders and challengers in next-generation sequencing
Figure 11: Examples of leaders and challengers in bioinformatics
Figure 12: Examples of leaders and challengers in gene therapy
Figure 13: Top therapy areas within antisense oligonucleotides
Figure 14: Who does what in the drug development space?
Figure 15: Our thematic screen ranks companies based on overall leadership in the 10 themes that matter most to their industry, generating a leading indicator of future performance
Figure 16: Our valuation screen ranks our universe of companies within a sector based on selected valuation metrics
Figure 17: Our risk screen ranks companies within a particular sector based on overall investment risk
